Cantor Fitzgerald Issues Pessimistic Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price

Janux Therapeutics (NASDAQ:JANX) had its price objective reduced by analysts at Cantor Fitzgerald from $150.00 to $100.00 in a report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock.

Several other equities research analysts have also commented on the stock. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Wedbush restated an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Stifel Nicolaus cut their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Guggenheim reduced their price target on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a research report on Friday. Finally, Bank of America lowered their price target on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $56.91.

Janux Therapeutics Stock Performance

JANX stock opened at $13.61 on Friday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The stock has a market capitalization of $818.64 million, a price-to-earnings ratio of -7.44 and a beta of 2.88. The stock’s fifty day moving average is $13.73 and its two-hundred day moving average is $20.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.14. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $0.08 million. As a group, analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Activity at Janux Therapeutics

In other news, insider Thomas Diraimondo sold 2,505 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $34,393.65. Following the sale, the insider owned 124,425 shares of the company’s stock, valued at approximately $1,708,355.25. The trade was a 1.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David Alan Campbell sold 8,072 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. This trade represents a 2.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 22,366 shares of company stock worth $371,245 in the last quarter. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several large investors have recently made changes to their positions in the business. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $34,000. Osaic Holdings Inc. boosted its holdings in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC grew its position in Janux Therapeutics by 37.9% in the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after buying an additional 1,011 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after buying an additional 2,502 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after acquiring an additional 820 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.